Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zevalin ibritumomab tiuxetan: Phase III

An interim analysis of 90 patients in IDPH’s 143-patient Phase III trial showed

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE